北京可瑞生物科技有限公司由多位北大校友和留学归国人员共同创立，致力于 基于T细胞受体（TCR）的创新药物开发。 可瑞生物通过技术革新，已经建立体系化的TCR研发平台解决了TCR克隆和优 化中的一系列技术难点，可以支持高效率地进行通量化TCR创新药开发；尤其是自 主研发的SMART-TCR亲和力优化平台，基于该革命性的TCR亲和力优化技术， 大幅提升了TCR亲和力优化的成功率和效率，突破了TCR创新药的开发壁垒。未来 可瑞生物将通过细胞治疗产品和可溶性TCR蛋白药物两种类型的产品，开发治疗肿 瘤、慢性感染和自身免疫疾病等方向的多种适应症，瞄准万亿级别的疾病市场。 

Beijing CorreGene Biotechnology Co., Ltd. Pioneering a New Era in TCR  Immunotherapy. Founded by several alumni of Peking University, Beijing CorreGene  Biotechnology Co., Ltd. is dedicated to the development of innovative therapeutics  based on T-cell receptors (TCRs). The company has established a comprehensive  research and development platform for TCR technology, which includes significant  breakthroughs in TCR cloning and affinity optimization.A key highlight is the  proprietary SMART-TCR affinity optimization platform, a revolutionary technology  that substantially increases the success rate and efficiency of TCR optimization. This  groundbreaking platform has effectively overcome previous challenges in developing  TCR-based medications.

地址：北京市昌平区生命科学园路21号国际精准医学加速中心北楼

三层

3rd Floor, North Building, Changfazhan International

Precision Medicine Acceleration Center, No.21

Shengmingyuan West Road, Changping District, Beijing

电话：86-010-86464526